These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 29235507)

  • 1. Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment.
    Gejl M; Brock B; Egefjord L; Vang K; Rungby J; Gjedde A
    Sci Rep; 2017 Dec; 7(1):17490. PubMed ID: 29235507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
    Femminella GD; Frangou E; Love SB; Busza G; Holmes C; Ritchie C; Lawrence R; McFarlane B; Tadros G; Ridha BH; Bannister C; Walker Z; Archer H; Coulthard E; Underwood BR; Prasanna A; Koranteng P; Karim S; Junaid K; McGuinness B; Nilforooshan R; Macharouthu A; Donaldson A; Thacker S; Russell G; Malik N; Mate V; Knight L; Kshemendran S; Harrison J; Hölscher C; Brooks DJ; Passmore AP; Ballard C; Edison P
    Trials; 2019 Apr; 20(1):191. PubMed ID: 30944040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
    Gejl M; Gjedde A; Egefjord L; Møller A; Hansen SB; Vang K; Rodell A; Brændgaard H; Gottrup H; Schacht A; Møller N; Brock B; Rungby J
    Front Aging Neurosci; 2016; 8():108. PubMed ID: 27252647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia.
    Gejl M; Egefjord L; Lerche S; Vang K; Bibby BM; Holst JJ; Mengel A; Møller N; Rungby J; Brock B; Gjedde A
    J Cereb Blood Flow Metab; 2012 Dec; 32(12):2146-52. PubMed ID: 22929437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
    Hunter K; Hölscher C
    BMC Neurosci; 2012 Mar; 13():33. PubMed ID: 22443187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.
    Egefjord L; Gejl M; Møller A; Brændgaard H; Gottrup H; Antropova O; Møller N; Poulsen HE; Gjedde A; Brock B; Rungby J
    Dan Med J; 2012 Oct; 59(10):A4519. PubMed ID: 23158895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
    García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P
    Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease.
    Watson KT; Wroolie TE; Tong G; Foland-Ross LC; Frangou S; Singh M; McIntyre RS; Roat-Shumway S; Myoraku A; Reiss AL; Rasgon NL
    Behav Brain Res; 2019 Jan; 356():271-278. PubMed ID: 30099030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
    Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
    PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.
    Stefanova E; Wall A; Almkvist O; Nilsson A; Forsberg A; Långström B; Nordberg A
    J Neural Transm (Vienna); 2006 Feb; 113(2):205-18. PubMed ID: 16049637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Niehoff ML; Morley JE; Jelsing J; Pyke C; Knudsen LB; Farr SA; Vrang N
    J Alzheimers Dis; 2015; 46(4):877-88. PubMed ID: 25869785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease.
    Ishii K; Imamura T; Sasaki M; Yamaji S; Sakamoto S; Kitagaki H; Hashimoto M; Hirono N; Shimomura T; Mori E
    Neurology; 1998 Jul; 51(1):125-30. PubMed ID: 9674790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans.
    Lerche S; Brock B; Rungby J; Bøtker HE; Møller N; Rodell A; Bibby BM; Holst JJ; Schmitz O; Gjedde A
    Diabetes; 2008 Feb; 57(2):325-31. PubMed ID: 17991759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
    Irie S; Matsumura Y; Zdravkovic M; Jacobsen LV; Kageyama S
    Int J Clin Pharmacol Ther; 2008 Jun; 46(6):273-9. PubMed ID: 18541123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.
    Salameh TS; Rhea EM; Talbot K; Banks WA
    Biochem Pharmacol; 2020 Oct; 180():114187. PubMed ID: 32755557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment.
    Nordberg A; Kadir A; Andreasen N; Almkvist O; Wall A; Långström B; Zetterberg H
    J Alzheimers Dis; 2015; 47(3):691-704. PubMed ID: 26401704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.